Breaking News on Biopharmaceutical Development & Manufacturing

Antibody, drug. Drug, antibody. Just like that.

Antibody-drug conjugates

Antibody-drug conjugates are one of the most active areas of biopharma research and investment for developers and contract manufacturing firms alike. In this section we will collate our coverage of this exciting market.

New dosing regimen brings Mylotarg reapproval for Pfizer

05-Sep-2017 - The US FDA has approved Mylotarg seven years after Pfizer withdrew the antibody-drug conjugate due to safety concerns and questions surrounding its clinical benefit.

ADC update: Jazz teams with ImmunoGen, Genmab inks pact with SeaGen

30-Aug-2017 - Jazz Pharmaceuticals has become the latest firm to team with ImmunoGen in an antibody-drug conjugate (ADC) collaboration.

Seattle Genetics gains first production site through $43m BMS plant buy

02-Aug-2017 - Seattle Genetics paid Bristol-Myers Squibb $17.8m for the biomanufacturing site and says it will spend a further $25.5m on equipment and improvements to support antibody production.

‘Dual-warhead’ a key differentiator for ADCs, says Synaffix

17-May-2017 - Antibody-drug conjugate (ADC) technology developer Synaffix has been granted a US patent for its dual-warhead HydraSpace platform.

Daiichi Sankyo pumping $135m into antibody-drug conjugate production

28-Apr-2017 - Daiichi Sankyo will plough ‎¥15bn ($135m) into three Japanese manufacturing facilities to support its antibody-drug conjugate pipeline.

RESPECT: find out what it means to ADCs, says Eisai subsidiary

07-Apr-2017 - Morphotek Inc has launched an antibody-drug conjugate (ADC) services business incorporating its RESPECT site-specific conjugation technology and eribulin-linker toxin platform.

Eleven Biotherapeutics: Taking on ADCs with targeted protein therapeutics

28-Mar-2017 - A two-step manufacturing process makes antibody-drug conjugate production expensive and causes stability issues, says Eleven Biotherapeutics which is fusing antibody fragments to cytotoxic proteins.

Goodwin Biotech to work on opioid addiction vaccines project

22-Mar-2017 - Contract manufacturer Goodwin Biotechnology will work with Minneapolis Medical Research Foundation (MMRF) to develop vaccines to treat opioid addiction.

US FDA lifts hold on Seattle Genetics' blood cancer ADC candidate

07-Mar-2017 - The US FDA has cleared Seattle Genetics to restart trials of its blood cancer candidate vadastuximab talirine that were halted last year after patient deaths. 

LegoChem signs up Novimmune as latest ADC licensee

24-Feb-2017 - LegoChem Biosciences has teamed up with Novimmune to develop and test antibody drug conjugate (ADC) drug.

Pfizer resubmits US and EU application for withdrawn ADC Mylotarg

01-Feb-2017 - Pfizer has resubmitted its antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) for regulatory review almost seven years after withdrawing it from the market.

Lundbeck banks on shark antibody delivery tech to cross blood-brain barrier

27-Jan-2017 - Shark antibodies are an attractive way to deliver biologics to the brain, says Ossianix which is using its blood-brain barrier (BBB) crossing technology in collaboration with Lundbeck.

Catalent sells rights to ADC candidate and gains development contract

12-Oct-2016 - Catalent will continue to develop and manufacture a non-Hodgkin’s Lymphoma antibody-drug conjugate (ADC) for Triphase Accelerator Corporation after licensing out the candidate.

Piramal: $53m Ash Stevens addition ‘synergistic’ with ADC business

18-Aug-2016 - The acquisition of Ash Stevens and a US high potent API facility will bolster Piramal’s antibody-drug conjugate offerings, the Indian CDMO says.

BIO 2016

Technology, not capacity, driving Catalent’s biologics strategy

14-Jun-2016 - Differentiated technologies buoyed by the recent $600m conjugation deal with Roche is driving Catalent’s biologics business, the firm told Biopharma-Reporter at BIO.

AbbVie adds stem cell-based ADC in $5.8bn Stemcentrx acquisition

29-Apr-2016 - AbbVie has added the late-stage antibody-drug conjugate (ADC) Rova-T to its pipeline through the $5.8bn acquisition of Stemcentrx.

Biotrinity 2016

Partnerships leading the way for Biopharma's immuno-oncology pipeline

27-Apr-2016 - Three deals in the last week signal AbbVie’s strategy in immuno-oncology but are just the latest examples of Big Biopharma’s trend for clinical partnerships.

BioCellChallenge granted US patent for antibody delivery tech

20-Apr-2016 - Triazamacrocyclic lipid complexes increase the efficiency of antibody-drug conjugates (ADCs) by delivering the payload right into the heart of a cancer cell, says BioCellChallenge.

Pfizer hits up four biotechs in $46m R&D collaboration strategy

19-Jan-2016 - Pfizer has invested $46m in separate collaborations with four R&D companies specialising in developing ADCs, immuno-oncology candidates and gene-therapies.

Pfizer hails CAB tech in ADC licensing deal with Bioatla

08-Dec-2015 - Pfizer and Bioatla have licensed each other’s technology platforms to develop ADCs with Conditionally Active Biologic (CAB) antibodies as the payload delivery vehicles.

Abzena to buy TCRS in latest boost to its ADC offering

24-Nov-2015 - Abzena is set to buy The Chemistry Research Solution (TCRS) in a deal one analyst says shows the firm’s intentions to dominate the bio-conjugation space.

CPhI Worldwide 2015

Profile of a CEO: Piramal Chief shares M&A plans

21-Oct-2015 - Piramal chief executive Vivek Sharma won last week’s CPhI award for the pharma industry’s CEO of the year. spoke to Sharma about his plans for the CDMO the day...

Althea building site for highly active bioproduction and ADCs

16-Oct-2015 - CDMO Ajinomoto Althea is opening a new facility to offer outsourced ADC (antibody drug conjugate) and HPAPI (highly potent active pharmaceutical ingredient) manufacturing, the Californian company has announced.

ADC Bio to build Welsh manufacturing site on back of antibody-drug demand

09-Oct-2015 - UK-based processing tech provider ADC Biotechnology will build a $10m plant for the GMP manufacture of antibody-drug conjugates (ADCs).

Roche's haemophilia A bispecific antibody granted USFDA breakthrough status

08-Sep-2015 - A bispecific antibody developed by Roche subsidiary Chugai has been granted Breakthrough Therapy Designation by the US FDA for the treatment of haemophilia A.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...